NORTHLAND(BJ:430047)2023-02-23 16:00Financial Performance - The company achieved operating revenue of ¥64,654,602.85, representing a year-on-year increase of 13.72%[5] - The net profit attributable to shareholders was -¥67,616,828.07, indicating a continued loss compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥70,703,823.19[5] - Basic earnings per share were -¥0.26, a decline from -¥0.20 in the previous year[5] - Total assets at the end of the reporting period were ¥345,231,281.15, a decrease of 1.53% year-on-year[5] - Shareholders' equity attributable to the company was ¥198,440,667.75, down 18.10% compared to the previous year[5] - The net asset value per share attributable to shareholders was ¥0.77, reflecting an 18.09% decrease year-on-year[5] Research and Development - The increase in research and development expenses was due to the initiation of clinical phase IIb for the new drug "Recombinant Human Thymosin β4"[6] - The company continues to operate at a loss as innovative drugs have not yet received commercial sales approval[6] Market Trends - The market penetration of ophthalmic drugs has been increasing, contributing to steady revenue growth in this segment[6]